Related Experiment Video
Updated: Aug 12, 2026
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Cognitive Effects of Prenatal Exposure to SSRIs in Children: A Systematic Review and Meta-Analysis
Fatima Shafiya Ali1, Huda Fatima1, Zainab Jasim Alqurain1
1General Medicine Practice, Batterjee Medical College, Jeddah, Saudi Arabia, bmc.edu.sa.
Insights
Prenatal exposure to Selective Serotonin Reuptake Inhibitors (SSRIs) was not linked to significant differences in children's cognitive, language, or motor development. This systematic review found no clinically meaningful impact on early neurodevelopmental outcomes.
Area of Science:
- Neuroscience
- Developmental Psychology
- Pharmacology
Background:
- Maternal depression and anxiety affect approximately 10% of pregnancies.
- Selective Serotonin Reuptake Inhibitors (SSRIs) are commonly prescribed, but their impact on fetal neurodevelopment is not fully understood.
- Serotonin's role in brain maturation raises concerns about prenatal SSRI exposure and later child development.
Purpose of the Study:
- To systematically review and meta-analyze evidence on the association between prenatal SSRI exposure and child neurodevelopmental outcomes.
- To evaluate effects on cognitive, language, and psychomotor development in children aged 0-18 years.
- To synthesize findings from cohort, case-control, and randomized studies.
Main Methods:
- Searched PubMed and Scopus databases through June 2025.
- Included studies reporting standardized neurodevelopmental outcomes in children with documented in utero SSRI exposure.
- Conducted random-effects meta-analyses to estimate standardized mean differences (SMDs) and 95% confidence intervals (CIs).
- Assessed study bias using the Newcastle-Ottawa Scale and RoB-2.
Main Results:
- Nine studies from 17 included records contributed to the meta-analysis.
- No significant difference in general cognition was found (SMD = -0.20; 95% CI -0.50 to 0.10).
- Secondary outcomes also showed no significant differences: receptive language (SMD = 0.04), expressive language (SMD = -0.17), and psychomotor development (SMD = -0.18).
- Sensitivity analyses, including SSRI-only cohorts, confirmed these findings.
Conclusions:
- Current evidence does not indicate a clinically significant impact of prenatal SSRI exposure on early cognitive, language, or psychomotor development.
- Observed effects were small and imprecise.
- Analyses restricted to SSRI-only cohorts and harmonized outcome measures further diminished any potential impact.
Background:
Depression and anxiety occur in about 10% of pregnancies. Selective serotonin reuptake inhibitors (SSRIs) are often prescribed, but their potential effects on fetal neurodevelopment remain uncertain. Because serotonin influences brain maturation, prenatal SSRI exposure may affect later cognition, language, or motor function.
Methods:
This systematic review and meta-analysis evaluated whether prenatal SSRI exposure is associated with differences in child cognitive, language, or psychomotor development. PubMed and Scopus were searched through June 2025 for cohort, case-control, or randomized studies reporting standardized neurodevelopmental outcomes in children (0-18 years) with documented in utero SSRI exposure compared with unexposed controls. Two reviewers independently screened studies, extracted data, and assessed bias (Newcastle-Ottawa Scale; RoB-2). Random-effects meta-analyses estimated standardized mean differences (SMDs) with 95% confidence intervals (CIs).
Results:
Of 250 records identified, 17 studies met inclusion criteria, and 9 contributed to meta-analysis. For general cognition, pooled SMD = -0.20 (95% CI -0.50 to 0.10) showed no significant difference between groups. Sensitivity analyses restricted to SSRI-only cohorts and Bayley-specific instruments yielded similar findings. Secondary outcomes also showed no differences: receptive language (SMD = 0.04; 95% CI -0.16 to 0.23), expressive language (SMD = -0.17; 95% CI -0.40 to 0.06), and psychomotor development (SMD = -0.18; 95% CI -0.67 to 0.31).
Conclusions:
Current evidence does not support a clinically meaningful impact of prenatal SSRI exposure on early cognitive, language, or psychomotor development. Observed effects were small, imprecise, and diminished when analyses were limited to SSRI-only cohorts and harmonized outcome measures.
